NasdaqGS - Delayed Quote USD

Cytokinetics, Incorporated (CYTK)

64.02 -1.25 (-1.92%)
At close: May 9 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Robert C. Wong VP & Chief Accounting Officer 495.72k -- 1968
Dr. Fady Ibraham Malik FACC, M.D., Ph.D. Executive Vice President of Research & Development 839.66k 586.17k 1964
Mr. Andrew M. Callos Executive VP & Chief Commercial Officer 752.84k -- 1969
Dr. James A. Spudich Ph.D. Co-Founder & Member of Scientific Advisory Board 21.94k -- 1942
Mr. Jeff Lotz Vice President of Sales & Operations -- -- --
Mr. Matt Yang Vice President of Corporate Finance and Financial Planning & Analysis -- -- --
Mr. Steven M. Cook Senior Vice President of Global Supply Chain Operations & Technical Operations -- -- 1959
Ms. Kari K. Loeser J.D. VP & Chief Compliance Officer -- -- --
Mr. John O. Faurescu Esq. VP, Associate General Counsel & Corporate Secretary -- -- --
Mr. Scott R. Jordan Senior Vice President of Global Marketing & Commercial Strategy -- -- --

Cytokinetics, Incorporated

350 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 624 3000 https://www.cytokinetics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
423

Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Corporate Governance

Cytokinetics, Incorporated’s ISS Governance QualityScore as of May 1, 2024 is 5. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 7; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Aug 01, 2024 - Aug 05, 2024
Cytokinetics, Incorporated Earnings Call

Related Tickers

BBIO BridgeBio Pharma, Inc.
28.73
+3.72%
 
CLRB Cellectar Biosciences, Inc.
3.2400
+1.25%
 
KRYS Krystal Biotech, Inc.
158.74
+0.67%
 
MDGL Madrigal Pharmaceuticals, Inc.
206.92
-0.54%
 
BPMC Blueprint Medicines Corporation
108.34
-0.40%
 
APLS Apellis Pharmaceuticals, Inc.
42.52
+0.52%
 
BHVN Biohaven Ltd.
41.36
+1.42%
 
JANX Janux Therapeutics, Inc.
51.94
-6.19%
 
SWTX SpringWorks Therapeutics, Inc.
42.95
+1.63%
 
IMVT Immunovant, Inc.
29.70
-0.20%